Area of Technology:Life Sciences
Title of the Innovation: Glucocorticoid Receptor (GR)-Targeted Liposomal Platform for Aggressive and Drug-Resistant Cancer
Brief About Innovation
Brief: The current technique can make drug-resistant tumours more susceptible to treatment thanks to a significant discovery that glucocorticoid receptors (GR) linked with cancer cells are selectively activated. Using this platform, many different drugs can be used to treat a variety of cancer types for which they are not typically used, in addition to the same cancer with acquired resistance.
Together, the technology has the potential to increase the life expectancy of cancer patients who have relapsed as well as lessen the immediate burden of discovering new drugs, which is prohibitively expensive.
Beta Version
Copyright © 2023. NRDC - All Rights Reserved
Designed and Developed by Maxtra Technologies.
